1Neurology® PodcastThe Neurology® podcast is introduced by Editor-in-Chief Robert A. Gross, MD, PhD, who discusses several highlighted articles in the current issue of the journal. The podcast features an interview with the author of an article in the current issue that summarizes the paper and discusses the main findings and clinical implications for neurologists. It concludes with the Lesson of the Week, a short segment on a topic such as a laboratory technique, statistical methods, or historical neurology. Podcast listeners can earn 0.5 AMA PRA Category 1 CME Credits by answering the multiple-choice questions in the online Podcast Quiz. The exams are posted weekly on Wednesday.

]]>http://www.aan.com/rss/?event=feed&channel=1en-uspbaskin@neurology.orgkwiersma@aan.comThu, 11 Aug 2011 15:22:12 GMTWed, 16 May 2012 15:00:08 GMTAXON RSS Extensionhttp://blogs.law.harvard.edu/tech/rss012320212223ThursdayFridaySaturdaySundayneurologypodcast@aan.comChannel Feedback263492582http://www.aan.comhttp://www.aan.com/rss/?event=feed&channel=1http://www.aan.com/rss/images/channels/channel_1_s.jpg144144The Neurology® podcast is introduced by Editor-in-Chief Robert A. Gross, MD, PhD, who discusses several highlighted articles in the current issue of the journal. The podcast features an interview with the author of an article in the current issue that summarizes the paper and discusses the main findings and clinical implications for neurologists. It concludes with the Lesson of the Week, a short segment on a topic such as a laboratory technique, statistical methods, or historical neurology. Podcast listeners can earn 0.5 AMA PRA Category 1 CME Credits by answering the multiple-choice questions in the online Podcast Quiz. The exams are posted weekly on Wednesday.Science & MedicinetrueAmerican Academy of Neurologycleanjournal,neurology,podcastManaging Editorpbaskin@neurology.orgWeekly podcast of content from Neurology®, the official journal of the American Academy of Neurology.The Neurology® podcast is introduced by Editor-in-Chief Robert A. Gross, MD, PhD, who discusses several highlighted articles in the current issue of the journal. The podcast features an interview with the author of an article in the current issue that summarizes the paper and discusses the main findings and clinical implications for neurologists. It concludes with the Lesson of the Week, a short segment on a topic such as a laboratory technique, statistical methods, or historical neurology. Podcast listeners can earn 0.5 AMA PRA Category 1 CME Credits by answering the multiple-choice questions in the online Podcast Quiz. The exams are posted weekly on Wednesday.23701Delayed Recall - March 2012http://www.aan.com/rss/index.cfm/getfile/AAN_2370.mp3Chafic Karam interviewing Mark Kupersmith about selected neuro-ophthalmology topics originally posted October 2011.

]]>http://www.aan.com/rss/index.cfm/getfile/AAN_2370.mp3tmb8r@virginia.eduThu, 01 Mar 2012 09:00:00 GMTAmerican Academy of Neurology2166cleanjournal,neurology,podcastSelected Neuro-Ophthalmology TopicsChafic Karam interviewing Mark Kupersmith about selected neuro-ophthalmology topics originally posted October 2011.23801March 6 2012 Issuehttp://www.aan.com/rss/index.cfm/getfile/AAN_2380.mp31) AAN policy on pharmaceutical and device industry support and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Mr. John Hutchins about his paper on AAN policy on pharmaceutical and device industry support. Dr. Stacey Clardy is reading our e-Pearl of the week about CSF biomarker in Alzheimer disease. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about clinical diagnostic reasoning and cognitive errors. Over the following weeks, Dr. Burns will interview Drs Groopman and Hartzband on an additional number of topics with week two about cognitive errors or biases that can influence our ability to diagnose. The participants had nothing to disclose except Mr. Hutchins, Drs. Burns, Clardy, Groopman and Hartzband.

Mr. Hutchins is currently the Associate General Counsel of the American Academy of Neurology and General Councel of the American Academy of Neurology Foundation.

Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..

Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section.

Dr. Groopman receives royalties from the publication of the book Your Medical Mind.

Dr. Hartzband receives royalties from the publication of the book Your Medical Mind.

]]>http://www.aan.com/rss/index.cfm/getfile/AAN_2380.mp3tmb8r@virginia.eduMon, 05 Mar 2012 11:00:00 GMTAmerican Academy of Neurology1273cleanjournal,neurology,podcastAAN policy on pharmaceutical and device industry support1) AAN policy on pharmaceutical and device industry support and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Mr. John Hutchins about his paper on AAN policy on pharmaceutical and device industry support. Dr. Stacey Clardy is reading our e-Pearl of the week about CSF biomarker in Alzheimer disease. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about clinical diagnostic reasoning and cognitive errors. Over the following weeks, Dr. Burns will interview Drs Groopman and Hartzband on an additional number of topics with week two about cognitive errors or biases that can influence our ability to diagnose. The participants had nothing to disclose except Mr. Hutchins, Drs. Burns, Clardy, Groopman and Hartzband. Mr. Hutchins is currently the Associate General Counsel of the American Academy of Neurology and General Councel of the American Academy of Neurology Foundation. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc.. Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Groopman receives royalties from the publication of the book Your Medical Mind. Dr. Hartzband receives royalties from the publication of the book Your Medical Mind. 23811March 13 2012 Issuehttp://www.aan.com/rss/index.cfm/getfile/AAN_2381.mp31) Cognition in the minimally-conscious state and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Thomas Cochrane interviews Dr. Damian Cruse about his paper on etiology and covert cognition in the minimally-conscious state. Dr. Stacey Clardy is reading our e-Pearl of the week about Moyamoya disease. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about cognitive errors or biases that can influence our ability to diagnose. Next week, Dr. Burns will interview Drs Groopman and Hartzband about risk-benefit ratios. The participants had nothing to disclose except Drs. Cochrane, Cruse, Clardy, Burns, Groopman and Hartzband.

Dr. Cochrane received royalties from the publication of the book First Aid for the Boards: Neurology.

Dr. Cruse has received research support from Medical Research Council UK and the Canada Excellence Research Chair Program.

Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section.

Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..

Dr. Groopman receives royalties from the publication of the book Your Medical Mind.

Dr. Hartzband receives royalties from the publication of the book Your Medical Mind.

]]>http://www.aan.com/rss/index.cfm/getfile/AAN_2381.mp3tmb8r@virginia.eduMon, 12 Mar 2012 22:00:00 GMTAmerican Academy of Neurology1202cleanjournal,neurology,podcastThe relationship between etiology and covert cognition in the minimally-conscious state1) Cognition in the minimally-conscious state and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Thomas Cochrane interviews Dr. Damian Cruse about his paper on etiology and covert cognition in the minimally-conscious state. Dr. Stacey Clardy is reading our e-Pearl of the week about Moyamoya disease. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about cognitive errors or biases that can influence our ability to diagnose. Next week, Dr. Burns will interview Drs Groopman and Hartzband about risk-benefit ratios. The participants had nothing to disclose except Drs. Cochrane, Cruse, Clardy, Burns, Groopman and Hartzband. Dr. Cochrane received royalties from the publication of the book First Aid for the Boards: Neurology. Dr. Cruse has received research support from Medical Research Council UK and the Canada Excellence Research Chair Program. Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc.. Dr. Groopman receives royalties from the publication of the book Your Medical Mind. Dr. Hartzband receives royalties from the publication of the book Your Medical Mind. 23831March 20 2012 Issuehttp://www.aan.com/rss/index.cfm/getfile/AAN_2383.mp31) Lamotrigine and aseptic meningitis and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michaela Tegan Chatman interviews Drs. Simms, Kortepeter and Avigan about their paper on lamotrigine and aseptic meningitis. Dr. Stacey Clardy is reading our e-Pearl of the week about pregnancy on the course of neuromyelitis optica. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about risk-benefit ratios. Next week, Dr. Burns will interview Drs Groopman and Hartzband about additional topics from their books and columns not previously discussed. The participants had nothing to disclose except Drs. Simms, Kortepeter, Avigan, Clardy, Burns, Groopman and Hartzband.

Dr. Simms is employed at U.S. Food and Drug Administration.

Dr. Kortepeter is employed at U.S. Food and Drug Administration.

Dr. Avigan is employed at U.S. Food and Drug Administration.

Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section.

Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..

Dr. Groopman receives royalties from the publication of the book Your Medical Mind.

Dr. Hartzband receives royalties from the publication of the book Your Medical Mind.

]]>http://www.aan.com/rss/index.cfm/getfile/AAN_2383.mp3tmb8r@virginia.eduMon, 19 Mar 2012 22:00:00 GMTAmerican Academy of Neurology1690cleanjournal,neurology,podcastLamotrigine and aseptic meningitis1) Lamotrigine and aseptic meningitis and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michaela Tegan Chatman interviews Drs. Simms, Kortepeter and Avigan about their paper on lamotrigine and aseptic meningitis. Dr. Stacey Clardy is reading our e-Pearl of the week about pregnancy on the course of neuromyelitis optica. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about risk-benefit ratios. Next week, Dr. Burns will interview Drs Groopman and Hartzband about additional topics from their books and columns not previously discussed. The participants had nothing to disclose except Drs. Simms, Kortepeter, Avigan, Clardy, Burns, Groopman and Hartzband. Dr. Simms is employed at U.S. Food and Drug Administration. Dr. Kortepeter is employed at U.S. Food and Drug Administration. Dr. Avigan is employed at U.S. Food and Drug Administration. Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc.. Dr. Groopman receives royalties from the publication of the book Your Medical Mind. Dr. Hartzband receives royalties from the publication of the book Your Medical Mind. 23851March 27 2012 Issuehttp://www.aan.com/rss/index.cfm/getfile/AAN_2385.mp31) Evidence-based guideline on intravenous immunoglobulin and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Huned Patwa about his paper on evidence-based guideline on intravenous immunoglobulin. Dr. Stacey Clardy is reading our e-Pearl of the week about chronic migraine prophylaxis. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about additional topics from their books and columns not previously discussed. The participants had nothing to disclose except Drs. Clardy, Burns, Groopman and Hartzband.

Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..

Dr. Patwa was an investigator in the ICE trial comparing IGIV with placebo for CIDP.

Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section.

Dr. Groopman receives royalties from the publication of the book Your Medical Mind.

Dr. Hartzband receives royalties from the publication of the book Your Medical Mind.

]]>http://www.aan.com/rss/index.cfm/getfile/AAN_2385.mp3tmb8r@virginia.eduMon, 26 Mar 2012 22:00:00 GMTAmerican Academy of Neurology1656cleanjournal,neurology,podcastEvidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders1) Evidence-based guideline on intravenous immunoglobulin and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Huned Patwa about his paper on evidence-based guideline on intravenous immunoglobulin. Dr. Stacey Clardy is reading our e-Pearl of the week about chronic migraine prophylaxis. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about additional topics from their books and columns not previously discussed. The participants had nothing to disclose except Drs. Clardy, Burns, Groopman and Hartzband. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc.. Dr. Patwa was an investigator in the ICE trial comparing IGIV with placebo for CIDP. Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Groopman receives royalties from the publication of the book Your Medical Mind. Dr. Hartzband receives royalties from the publication of the book Your Medical Mind. 23861Delayed Recall - April 2012http://www.aan.com/rss/index.cfm/getfile/AAN_2386.mp3Evaluation of dizziness in a patient.

]]>http://www.aan.com/rss/index.cfm/getfile/AAN_2386.mp3tmb8r@virginia.eduSun, 01 Apr 2012 08:00:00 GMTAmerican Academy of Neurology2640cleanjournal,neurology,podcastEvaluation of dizziness in a patient.Evaluation of dizziness in a patient.23871April 3 2012 Issuehttp://www.aan.com/rss/index.cfm/getfile/AAN_2387.mp31) Long term remission in CIDP and 2) Topic of the month: Obesity and the neurology patient. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Filip Eftimov about his paper on long term remission in CIDP. Dr. Chafic Karam is reading our e-Pearl of the week about acute basilar artery occlusion. In the next part of the podcast Dr. Ted Burns interviews Dr. Beau Bruce about obesity in Idiopathic intracranial hypertension. Drs. Burns & Kissela with interview others about obesity and the neurology patient. The participants had nothing to disclose except Drs. Burns, Eftimov, Karam, and Bruce.

Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..

Dr. Eftimov received payment from Sanquin Blood Supply Foundation for a single lecture to nurses providing home-care immunoglobulin therapy.

Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section.

Dr. Bruce receives research support as recipientof AAN/AANF Practice Research Fellowship and is funded by NIH grants UL1-RR025008 & KL2-RR025009.


]]>http://www.aan.com/rss/index.cfm/getfile/AAN_2387.mp3tmb8r@virginia.eduMon, 02 Apr 2012 22:00:00 GMTAmerican Academy of Neurology1607cleanjournal,neurology,podcastLong term remission in CIDP patients after pulsed dexamethasone or short prednisolone treatment1) Long term remission in CIDP and 2) Topic of the month: Obesity and the neurology patient. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Filip Eftimov about his paper on long term remission in CIDP. Dr. Chafic Karam is reading our e-Pearl of the week about acute basilar artery occlusion. In the next part of the podcast Dr. Ted Burns interviews Dr. Beau Bruce about obesity in Idiopathic intracranial hypertension. Drs. Burns & Kissela with interview others about obesity and the neurology patient. The participants had nothing to disclose except Drs. Burns, Eftimov, Karam, and Bruce. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc.. Dr. Eftimov received payment from Sanquin Blood Supply Foundation for a single lecture to nurses providing home-care immunoglobulin therapy. Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Bruce receives research support as recipientof AAN/AANF Practice Research Fellowship and is funded by NIH grants UL1-RR025008 & KL2-RR025009. 23901April 10 2012 Issuehttp://www.aan.com/rss/index.cfm/getfile/AAN_2390.mp31) Developing epilepsy after febrile seizures and 2) Topic of the month: Obesity and the neurology patient. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Levy Sander about his paper on developing epilepsy after febrile seizures. Dr. Chafic Karam is reading our e-Pearl of the week about neuromyelitis optica. In the next part of the podcast Dr. Ted Burns interviews Dr. Jeff Burns about the link between dementia and obesity. Next week, Dr. Brett Kissela will interview Dr. Mitch Elkind about stroke and obesity. The participants had nothing to disclose except Prof. Sander, Drs. Karam, Ted Burns, and Jeff Burns.

Prof. Sander serves on scientific advisory boards for GlaxoSmithKline, Eisai Inc., ViroPharma Incorporated, and UCB; has received funding for travel from UCB and Janssen; serves on the editorial boards of Lancet Neurology, Epileptic Disorders, and Epilepsia; serves on the speakers' bureaus of UCB and GlaxoSmithKline; received research support from UCB (institutional), the NIH, CBRC, European Union Seventh Framework Programme, Wellcome Trust, National Epilepsie Fonds Nederland, and The Brain Research Trust; and his current post is endowed by the UK Epilepsy Society.

Dr. Karam serves on the editorial team for the Neurology Resident and Fellow Section.

Dr. Ted Burns serves as Podcast Editor for Neurology; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..

Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers' bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.

Prof. Sander serves on scientific advisory boards for GlaxoSmithKline, Eisai Inc., ViroPharma Incorporated, and UCB; has received funding for travel from UCB and Janssen; serves on the editorial boards of Lancet Neurology, Epileptic Disorders, and Epilepsia; serves on the speakers' bureaus of UCB and GlaxoSmithKline; received research support from UCB (institutional), the NIH, CBRC, European Union Seventh Framework Programme, Wellcome Trust, National Epilepsie Fonds Nederland, and The Brain Research Trust; and his current post is endowed by the UK Epilepsy Society.

Dr. Karam serves on the editorial team for the Neurology Resident and Fellow Section.

Dr. Ted Burns serves as Podcast Editor for Neurology; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..

Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers' bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.

]]>http://www.aan.com/rss/index.cfm/getfile/AAN_2390.mp3tmb8r@virginia.eduMon, 09 Apr 2012 22:00:00 GMTAmerican Academy of Neurology1113cleanjournal,neurology,podcastThe long-term risk of developing epilepsy after febrile seizures: A prospective cohort study1) Developing epilepsy after febrile seizures and 2) Topic of the month: Obesity and the neurology patient. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Levy Sander about his paper on developing epilepsy after febrile seizures. Dr. Chafic Karam is reading our e-Pearl of the week about neuromyelitis optica. In the next part of the podcast Dr. Ted Burns interviews Dr. Jeff Burns about the link between dementia and obesity. Next week, Dr. Brett Kissela will interview Dr. Mitch Elkind about stroke and obesity. The participants had nothing to disclose except Prof. Sander, Drs. Karam, Ted Burns, and Jeff Burns. Prof. Sander serves on scientific advisory boards for GlaxoSmithKline, Eisai Inc., ViroPharma Incorporated, and UCB; has received funding for travel from UCB and Janssen; serves on the editorial boards of Lancet Neurology, Epileptic Disorders, and Epilepsia; serves on the speakers' bureaus of UCB and GlaxoSmithKline; received research support from UCB (institutional), the NIH, CBRC, European Union Seventh Framework Programme, Wellcome Trust, National Epilepsie Fonds Nederland, and The Brain Research Trust; and his current post is endowed by the UK Epilepsy Society. Dr. Karam serves on the editorial team for the Neurology Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc.. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers' bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency. Prof. Sander serves on scientific advisory boards for GlaxoSmithKline, Eisai Inc., ViroPharma Incorporated, and UCB; has received funding for travel from UCB and Janssen; serves on the editorial boards of Lancet Neurology, Epileptic Disorders, and Epilepsia; serves on the speakers' bureaus of UCB and GlaxoSmithKline; received research support from UCB (institutional), the NIH, CBRC, European Union Seventh Framework Programme, Wellcome Trust, National Epilepsie Fonds Nederland, and The Brain Research Trust; and his current post is endowed by the UK Epilepsy Society. Dr. Karam serves on the editorial team for the Neurology Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc.. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers' bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency. 23921April 17 2012 Issuehttp://www.aan.com/rss/index.cfm/getfile/AAN_2392.mp31) Antidepressants in Parkinson disease and 2) Topic of the month: Obesity and the neurology patient. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matt Barrett interviews Dr. Irene Richard about her paper on antidepressants in Parkinson disease. Dr. Chafic Karam is reading our e-Pearl of the week about migraine without aura. In the next part of the podcast Dr. Brett Kissela interviews Dr. Mitch Elkind about stroke and obesity. Next week, Dr. Burns will interview Dr. Lisa Davis about her recent paper published in the March Neurology Clinical Practice Journal. The participants had nothing to disclose except Drs. Richard, Karam, Kissela, and Elkind.

Dr. Richard serves on a scientific advisory board for the Michael J. Fox Foundation; has received a speaker honorarium from Teva Pharmaceutical Industries Ltd.; and receives/has received research support from Neurologix, Inc., Eli Lilly and Company, the NIH/NINDS, Cornell University, and the Michael J. Fox Foundation.

Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section.

Dr. Kissela serves on scientific advisory boards for Northstar Neuroscience and Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from NexStim and the NIH, and provides medico-legal reviews.

Dr. Elkind serves as the Associate Editor of the Neurology® Resident and Fellow Section, serves on an event adjudication committee for Jarvik Heart, receives research support from the NIH, diaDexus, Inc. Sanofi-Aventis, serves on the New York City and Founders Affiliate Boards for the American Heart Association, and has served as a consultant in stroke litigation-legal proceedings.

]]>http://www.aan.com/rss/index.cfm/getfile/AAN_2392.mp3tmb8r@virginia.eduMon, 16 Apr 2012 22:00:00 GMTAmerican Academy of Neurology1367cleanjournal,neurology,podcastA randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease1) Antidepressants in Parkinson disease and 2) Topic of the month: Obesity and the neurology patient. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matt Barrett interviews Dr. Irene Richard about her paper on antidepressants in Parkinson disease. Dr. Chafic Karam is reading our e-Pearl of the week about migraine without aura. In the next part of the podcast Dr. Brett Kissela interviews Dr. Mitch Elkind about stroke and obesity. Next week, Dr. Burns will interview Dr. Lisa Davis about her recent paper published in the March Neurology Clinical Practice Journal. The participants had nothing to disclose except Drs. Richard, Karam, Kissela, and Elkind. Dr. Richard serves on a scientific advisory board for the Michael J. Fox Foundation; has received a speaker honorarium from Teva Pharmaceutical Industries Ltd.; and receives/has received research support from Neurologix, Inc., Eli Lilly and Company, the NIH/NINDS, Cornell University, and the Michael J. Fox Foundation. Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kissela serves on scientific advisory boards for Northstar Neuroscience and Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from NexStim and the NIH, and provides medico-legal reviews. Dr. Elkind serves as the Associate Editor of the Neurology® Resident and Fellow Section, serves on an event adjudication committee for Jarvik Heart, receives research support from the NIH, diaDexus, Inc. Sanofi-Aventis, serves on the New York City and Founders Affiliate Boards for the American Heart Association, and has served as a consultant in stroke litigation-legal proceedings. 23931April 24 2012 Issuehttp://www.aan.com/rss/index.cfm/getfile/AAN_2393.mp31) Evidence-based guideline updates on episodic migraine prevention and 2) Topic of the month: Obesity and the neurology patient. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Drs. Stephen D. Silberstein and Starr Holland on the guideline updates about treatments for episodic migraine prevention in adults. Dr. Chafic Karam is reading our e-Pearl of the week about scapular winging. In the next part of the podcast Dr. Ted Burns interviews Dr. Lisa Davis about her recent paper titled: Clinical strategies for managing the overweight neurology patient published in the March Neurology Clinical Practice Journal. All participants have disclosures.

Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..

Dr. Silberstein serves on scientific advisory boards for AGA Medical Corporation, Allergan, Inc., Amgen, CAPNIA, Coherex Medical, GlaxoSmithKline, Iroko Pharmaceuticals, LLC, Eli Lilly and Company, MAP Pharmaceuticals, Inc., Medtronic, Inc., Merck Serono, Neuralieve Inc., the NIH/NINDS, NuPathe Inc., Pfizer Inc, and St. Jude Medical; serves on the editorial boards of Cephalalgia and Current Pain and Headache Reports; serves on the speakers' bureaus for Allergan, Inc., Endo Pharmaceuticals, GlaxoSmithKline, Zogenix, and Merck Serono; serves as a consultant for Amgen, Nautilus, Inc., Novartis, Opti-Nose, and Zogenix; receives publishing royalties for Wolff's Headache, 8th edition (Oxford University Press, 2009) and Handbook of Headache (Cambridge University Press, 2010); his employer receives research support from Allergan, Endo, GlaxoSmithKline, MAP, Merck Serono, the NIH/NINDS, Novartis, and Neurolieve; receives research support from the American Headache Society and the International Headache Society.

Dr. Holland serves as a consultant for MAP Pharmaceuticals, Inc.; receives research support from Albert Einstein College of Medicine and the American Headache Society.

Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section.

Dr. Davis serves as a consultant for Medifast, Inc. and the Coleman Research Group and is a shareholder in Medifast, Inc.

]]>http://www.aan.com/rss/index.cfm/getfile/AAN_2393.mp3tmb8r@virginia.eduMon, 23 Apr 2012 22:00:00 GMTAmerican Academy of Neurology1581cleanjournal,neurology,podcastEvidence-based Guideline Update: Nonstandard Prescription Medications, NSAIDs, and Other OTC Treatments for Episodic Migraine Prevention in Adults Evidence-based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults 1) Evidence-based guideline updates on episodic migraine prevention and 2) Topic of the month: Obesity and the neurology patient. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Drs. Stephen D. Silberstein and Starr Holland on the guideline updates about treatments for episodic migraine prevention in adults. Dr. Chafic Karam is reading our e-Pearl of the week about scapular winging. In the next part of the podcast Dr. Ted Burns interviews Dr. Lisa Davis about her recent paper titled: Clinical strategies for managing the overweight neurology patient published in the March Neurology Clinical Practice Journal. All participants have disclosures. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc.. Dr. Silberstein serves on scientific advisory boards for AGA Medical Corporation, Allergan, Inc., Amgen, CAPNIA, Coherex Medical, GlaxoSmithKline, Iroko Pharmaceuticals, LLC, Eli Lilly and Company, MAP Pharmaceuticals, Inc., Medtronic, Inc., Merck Serono, Neuralieve Inc., the NIH/NINDS, NuPathe Inc., Pfizer Inc, and St. Jude Medical; serves on the editorial boards of Cephalalgia and Current Pain and Headache Reports; serves on the speakers' bureaus for Allergan, Inc., Endo Pharmaceuticals, GlaxoSmithKline, Zogenix, and Merck Serono; serves as a consultant for Amgen, Nautilus, Inc., Novartis, Opti-Nose, and Zogenix; receives publishing royalties for Wolff's Headache, 8th edition (Oxford University Press, 2009) and Handbook of Headache (Cambridge University Press, 2010); his employer receives research support from Allergan, Endo, GlaxoSmithKline, MAP, Merck Serono, the NIH/NINDS, Novartis, and Neurolieve; receives research support from the American Headache Society and the International Headache Society. Dr. Holland serves as a consultant for MAP Pharmaceuticals, Inc.; receives research support from Albert Einstein College of Medicine and the American Headache Society. Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Davis serves as a consultant for Medifast, Inc. and the Coleman Research Group and is a shareholder in Medifast, Inc. 24041May 1 2012 Issuehttp://www.aan.com/rss/index.cfm/getfile/AAN_2404.mp31) Simultaneous PML-IRIS in MS and 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Igor Koralnik about his paper on simultaneous PML-IRIS in an MS patient. Dr. Jennifer Fugate is reading our e-Pearl of the week about traumatic brain injury. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about clinical diagnosis of mild cognitive impairment. Over the upcoming weeks they will discuss a number of topics related to mild cognitive impairment and Alzheimer disease. All participants have disclosures.

Dr. Keegan serves as eMedicine Chief Editor and is a consultant for Bionest and Novartis.

Dr. Koralnik serves on the editorial board of the Journal of NeuroVirology; served on the scientific advisory boards for Hoffman-La Roche Inc., GlaxoSmithKline and Merck Serono; receives royalties from UpToDate, Inc.; has served as a consultant for Bristol-Myers Squibb, Ono Pharmaceuticals Co. LTD., Merck Serone, Hoffman-La Roche Inc., GlaxoSmithKline, Perseid Therapeutic LLC; Vertex Pharmaceuticals; and Johnson & Johnson; receives research support from NIH; and has received research support from Biogen Idec and the National Multiple Sclerosis Society.

Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section.

Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers' bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.

Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.

]]>http://www.aan.com/rss/index.cfm/getfile/AAN_2404.mp3tmb8r@virginia.eduMon, 30 Apr 2012 22:00:00 GMTAmerican Academy of Neurology1307cleanjournal,neurology,podcastSimultaneous PML-IRIS after discontinuation of natalizumab in an MS patient1) Simultaneous PML-IRIS in MS and 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Igor Koralnik about his paper on simultaneous PML-IRIS in an MS patient. Dr. Jennifer Fugate is reading our e-Pearl of the week about traumatic brain injury. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about clinical diagnosis of mild cognitive impairment. Over the upcoming weeks they will discuss a number of topics related to mild cognitive impairment and Alzheimer disease. All participants have disclosures. Dr. Keegan serves as eMedicine Chief Editor and is a consultant for Bionest and Novartis. Dr. Koralnik serves on the editorial board of the Journal of NeuroVirology; served on the scientific advisory boards for Hoffman-La Roche Inc., GlaxoSmithKline and Merck Serono; receives royalties from UpToDate, Inc.; has served as a consultant for Bristol-Myers Squibb, Ono Pharmaceuticals Co. LTD., Merck Serone, Hoffman-La Roche Inc., GlaxoSmithKline, Perseid Therapeutic LLC; Vertex Pharmaceuticals; and Johnson & Johnson; receives research support from NIH; and has received research support from Biogen Idec and the National Multiple Sclerosis Society. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers' bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency. Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.24051Delayed Recall - May 2012http://www.aan.com/rss/index.cfm/getfile/AAN_2405.mp3Neuromuscular Junction Disorders

]]>http://www.aan.com/rss/index.cfm/getfile/AAN_2405.mp3tmb8r@virginia.eduTue, 01 May 2012 08:00:00 GMTAmerican Academy of Neurology1996cleanjournal,neurology,podcastNeuromuscular Junction DisordersNeuromuscular Junction Disorders24061May 8 2012 Issuehttp://www.aan.com/rss/index.cfm/getfile/AAN_2406.mp31) A case of Necrotizing myopathy 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Mammen interviews Prof. Michael Hanna about his paper on necrotizing myopathy. Dr. Jennifer Fugate is reading our e-Pearl of the week about unilateral clubbing in hemiplegia. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about clinical diagnosis of Alzheimer disease. Over the upcoming weeks they will discuss a number of topics related to mild cognitive impairment and Alzheimer disease. All participants have disclosures.

Dr. Mammen has served as an expert witness for trials in 2010 and 2011; receives revenue for a patent on anti-HMGCR antibody detection technology; and received honoraria for Grand Round presentations at several universities.

Prof. Hanna receives research funding from the Medical Research Council, MRC Center grant (G0601943), from the Muscular Dystrophy Campaign and the Consortium for Clinical Investigation of Neurological Channelopathies (CINCH) NIH grant U54 NS059065. M.G. Hanna provides the UK national patient referral center for skeletal muscle channelopathies funded by the UK Department of Health National Commissioning Group.

Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section.

Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.

Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.

]]>http://www.aan.com/rss/index.cfm/getfile/AAN_2406.mp3tmb8r@virginia.eduMon, 07 May 2012 22:00:00 GMTAmerican Academy of Neurology1539cleanjournal,neurology,podcastA case of necrotizing myopathy with proximal weakness and cardiomyopathy1) A case of Necrotizing myopathy 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Mammen interviews Prof. Michael Hanna about his paper on necrotizing myopathy. Dr. Jennifer Fugate is reading our e-Pearl of the week about unilateral clubbing in hemiplegia. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about clinical diagnosis of Alzheimer disease. Over the upcoming weeks they will discuss a number of topics related to mild cognitive impairment and Alzheimer disease. All participants have disclosures. Dr. Mammen has served as an expert witness for trials in 2010 and 2011; receives revenue for a patent on anti-HMGCR antibody detection technology; and received honoraria for Grand Round presentations at several universities. Prof. Hanna receives research funding from the Medical Research Council, MRC Center grant (G0601943), from the Muscular Dystrophy Campaign and the Consortium for Clinical Investigation of Neurological Channelopathies (CINCH) NIH grant U54 NS059065. M.G. Hanna provides the UK national patient referral center for skeletal muscle channelopathies funded by the UK Department of Health National Commissioning Group. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency. Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc. 24071May 15 2012 Issuehttp://www.aan.com/rss/index.cfm/getfile/AAN_2407.mp31) Newly diagnosed epilepsy 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jen Lander interviews Prof. Martin Brodie about his paper on newly diagnosed epilepsy. Dr. Jennifer Fugate is reading our e-Pearl of the week about nocturnal wandering in adults. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about imaging modalities for diagnosis of mild cognitive impairment and Alzheimer disease. Over the next two weeks they will discuss a number of topics related to mild cognitive impairment and Alzheimer disease. The participants had nothing to disclose except Prof. Brodie, Drs. Fugate, Burns and Morris.

Prof. Brodie serves on the editorial boards of Seizure, Epilepsy & Behavior, CNS Drugs and Acta Neurologica Scandinavia; serves on scientific advisory boards for Pfizer Inc, UCB, Eisai Inc., GlaxoSmithKline, Novartis, Sanofi-aventis, Upsher-Smith Laboratories, Inc. and Lundbeck Inc; has received funding for travel from UCB; serves as a consultant for Eisai Inc.; serves on speakers' bureaus for UCB, GlaxoSmithKline, and Eisai Inc.; and has received research support from GlaxoSmithKline, and Eisai Inc.

Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section.

Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.

Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.

]]>http://www.aan.com/rss/index.cfm/getfile/AAN_2407.mp3tmb8r@virginia.eduMon, 14 May 2012 22:00:00 GMTAmerican Academy of Neurology1544cleanjournal,neurology,podcastPatterns of treatment response in newly diagnosed epilepsy1) Newly diagnosed epilepsy 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jen Lander interviews Prof. Martin Brodie about his paper on newly diagnosed epilepsy. Dr. Jennifer Fugate is reading our e-Pearl of the week about nocturnal wandering in adults. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about imaging modalities for diagnosis of mild cognitive impairment and Alzheimer disease. Over the next two weeks they will discuss a number of topics related to mild cognitive impairment and Alzheimer disease. The participants had nothing to disclose except Prof. Brodie, Drs. Fugate, Burns and Morris. Prof. Brodie serves on the editorial boards of Seizure, Epilepsy & Behavior, CNS Drugs and Acta Neurologica Scandinavia; serves on scientific advisory boards for Pfizer Inc, UCB, Eisai Inc., GlaxoSmithKline, Novartis, Sanofi-aventis, Upsher-Smith Laboratories, Inc. and Lundbeck Inc; has received funding for travel from UCB; serves as a consultant for Eisai Inc.; serves on speakers' bureaus for UCB, GlaxoSmithKline, and Eisai Inc.; and has received research support from GlaxoSmithKline, and Eisai Inc. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency. Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.